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small amounts ofM and L protein asminor components of S-HBsAg par-
ticles. It has superior immunogenicity (Shouval et al., 2015), but it re-
mains open whether this is due to the preS components or to better
immunogenicity of the S part. Isolated preS antigen without HBsAg
had generated neutralizing antibodies in experimental animalsHepatitis B is an old disease and the possibility to successfully vacci-
nate against infection by hepatitis B virus (HBV) was ﬁrst shown
36 years ago in a convincing trial (Szmuness et al., 1980). Thus, it may
appear unspectacular when in this issue of EBioMedicine, a small clinical
trial with a new type of hepatitis B vaccine is described (Cornelius et al.,
2016). Do we really need this? But the signiﬁcance of the paper should
not be underestimated. The classical hepatitis B vaccine is produced in
genetically transformed yeast cells and consists of 20-nm-large particles
formed by the small (S) protein of hepatitis B surface antigen (HBsAg).
The antibodies against conformational epitopes of HBsAg (anti-HBs)
neutralize the infectivity of hepatitis B virus (HBV) in vitro and indicate
protection in vivo. However, the classical vaccine has some shortcom-
ings. In spite of multiple injections some persons remain unprotected,
particularly those with a weakened immune response. Furthermore,
asymptomatic infections by heterologousHBV genotypeswith transient
viremia are frequent in vaccinated subjects with low or moderate anti-
HBs titers (for review see Gerlich, 2015). While theWHO, public health
authorities and the main producers of hepatitis B vaccines still consider
these drawbacks as insigniﬁcant, an enhanced protective capacity
against a wider HBV genotype spectrum would not hurt.
A weakness of the current HBV vaccines is that they were designed
at a time when the S protein was believed to be the only component
of the viral envelope. Soon after, two related, larger HBV envelope pro-
teins (L for large and M for middle) were discovered (Heermann et al.,
1984). L protein consists of the S sequence and an amino-terminal
preS part which is further divided into preS1 and preS2. PreS2 forms
the aminoterminal part of M. The preS1 domain of L was identiﬁed as
the species-, liver- and differentiation-speciﬁc attachment site of HBVom.2016.07.023.
ssen.de (W.H. Gerlich),
. This is an open access article underto liver cells (Glebe et al., 2005). Currently, a not widely used vaccine
is available which is expressed inmammalian cell cultures and contains
(Neurath et al., 1986) but was never administered to human recipients
as a vaccine until the study performed by Cornelius et al. It is an irony of
medicine history that this study was not intended to improve immuni-
zation against HBV but is a side product during the development of an
immunotherapy against grass pollen allergy. The Valenta group fused
DNA sequences encoding grass pollen allergen-speciﬁc peptides to the
preS sequence, expressed this construct in E. coli, and obtained after pu-
riﬁcation a vaccine called BM32. This vaccine was adsorbed to alumi-
num hydroxide and given in doses of 10–40 μg (similar to the classical
hepatitis B vaccine) to 30 human subjects. BM32 satisﬁed the expecta-
tions as grass pollen allergy immunotherapeutic, but the question of
the current paper was: what was the effect of the preS carrier protein?
Soluble monomeric proteins like the preS antigen are usually weak im-
munogens, but the data suggest that the antibody and T-cell responses
against preS partial peptides are comparable to those against the classi-
cal HBsAg although no direct comparison was done. It remains open
whether the allergen components changed the immune response
against preS. It should be noted that a partial lipopeptide of preS1 linked
with aminoterminal myristic acid is able to compete with natural HBV
for its receptor and is used as the candidate drug Myrcludex in clinical
studies for patients with chronic HBV and hepatitis delta virus infection
(Blank et al., 2016); but this drug candidate is not a vaccine.
Remarkably, Cornelius et al. report for the ﬁrst time HBV-
neutralizing antibodies in all seven so-far tested human recipients of
the BM32 vaccine, i.e., of preS antigen without other HBV antigens.
Assay of neutralizing antibodies has been difﬁcult because for long
time the only HBV-susceptible cell cultures were human, ape or Tupaia
hepatocyte explants which are of very limited availability. Since it is
known that the preS1 attachment site binds to the sodium-dependent
taurocholate cotransporting peptide (NTCP), a bile acid transporter
which mediates entry of HBV (Yan et al., 2012), it became possible to
create NTCP-expressing hepatic cell lines susceptible for HBV which
the authors have applied. The number of the vaccine recipients evaluat-
ed is small and no titers were determined, but the data are sufﬁcient tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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antibodies.
The construct contained both preS1 and preS2. The N-terminal part
of preS1 is the binding site for NTCP, and antibodies against this part
were shown to neutralize HBV (Glebe et al., 2003; Bremer et al., 2011)
while the C-terminal part is immunogenic but does not induce neutral-
izing antibodies. The preS2 part is nonessential for HBV and antibodies
against preS2 may be dispensable, but the preS2 part may provide T
helper epitopes. An important reason to focus on preS1-based hepatitis
B vaccines is the fact that L protein is enriched in the HBV particle while
the S and M protein are most abundant on noninfectious HBsAg parti-
cles (Heermann et al., 1984). These are present in 3000-fold excess
and may consume the neutralizing antibodies against them. Contrary
to the protective HBsAg epitopes, the preS epitopes are sequential, rela-
tively well conserved between the HBV genotypes and have not yet
been subject to escape mutations. It appears possible that the paper
from Cornelius et al. may encourage the ﬁeld to re-vitalize research on
hepatitis B vaccines.
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